Survival and neutrophil kinetics in infants with severe group B streptococcal disease treated with gamma globulin

Area of Science:

• Neonatal Medicine
• Immunology
• Infectious Diseases

Background:

• Neonatal group B streptococcal (GBS) disease is a significant cause of sepsis in newborns.
• Neutropenia, a low neutrophil count, is associated with increased mortality in GBS sepsis.
• Intravenous gamma globulin (IVIG) is a potential immunomodulatory therapy.

Purpose of the Study:

• To evaluate the efficacy of IVIG as an adjunct therapy for severe neonatal GBS disease, particularly in cases with neutropenia.
• To assess the impact of IVIG on survival rates and neutrophil recovery in affected infants.

Main Methods:

• Retrospective review of hospital records for 67 infants with confirmed early-onset GBS sepsis and neutropenia.
• Comparison of mortality rates between infants who received antibiotics with or without IVIG.
• Analysis of neutrophil counts and survival outcomes in relation to IVIG administration, including subgroup analysis for low birth weight infants.

Main Results:

• Mortality rate was significantly lower in infants receiving antibiotics plus IVIG (18%) compared to those receiving antibiotics alone (39%) (p < 0.05).
• For low birth weight infants, IVIG administration was associated with a reduced mortality rate (20% vs. 48%) (p < 0.03).
• Survivors treated with IVIG exhibited a more rapid increase in neutrophil counts compared to non-IVIG treated survivors.

Conclusions:

• Adjunct therapy with intravenous gamma globulin appears to improve survival in neonatal GBS disease associated with neutropenia.
• IVIG may promote a faster neutrophil count recovery, contributing to better outcomes.
• This retrospective study suggests IVIG is a beneficial adjunctive treatment for severe neonatal GBS sepsis.